Ayala Pharm - ADXS STOCK NEWS

Advaxis, Inc. (Nasdaq: ADXS) has received an extension until November 22, 2021, from the Nasdaq Hearings Panel to comply with the $1.00 Minimum Bid Price Rule while completing its merger with Biosight, Ltd. The merger aims to enhance Advaxis's portfolio in hematological therapies. Upon closure, the combined entity must meet Nasdaq's initial listing requirements, including a $4 per share price. Although there are no guarantees, Advaxis is optimistic about fulfilling these criteria and closing the merger by the deadline.

Advaxis, Inc. has initiated a Phase 1 clinical study of ADXS-504, an off-the-shelf neoantigen immunotherapy, targeting biochemically recurrent prostate cancer. Conducted at Columbia University, this study represents the first evaluation of ADXS-504 in this patient group. The trial will assess safety, tolerability, and preliminary clinical responses, involving 9-18 participants receiving the treatment every four weeks. ADXS-504 aims to elicit T cell responses against multiple tumor antigens, potentially delaying the start of androgen blockade therapy. The company aims to expand its ADXS-HOT program with this new application.

Advaxis, a clinical-stage biotechnology company, will present data from its Phase 1/2 study of ADXS-503 combined with Pembrolizumab for treating metastatic non-small cell lung cancer at the Non-Small Cell Lung Cancer Drug Development Summit on July 15, 2021. The presentation by Andres Gutierrez, M.D. focuses on the potential of neoantigen immunotherapies to overcome resistance to PD-1 inhibitors. The session will take place virtually at 9:30 AM EDT.

Advaxis is dedicated to advancing immunotherapy products using bioengineered Listeria monocytogenes.

The merger between Advaxis and Biosight aims to establish Biosight Therapeutics, focusing on advancing clinical-stage oncology programs, particularly aspacytarabine (BST-236) for treating Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Post-merger, the company expects approximately $50 million in cash. Key milestones in the next 12-18 months include Phase 2 trial results and new trials. The merger has received unanimous board approval, with Biosight shareholders owning 75% of the new entity, which will trade as BSTX on Nasdaq.

Advaxis, Inc. (ADXS) announced Phase 1/2 trial data for ADXS-503 at ASCO 2021, demonstrating a 44% disease control rate in patients who previously failed KEYTRUDA®. The therapy showed durable clinical benefits, including stable disease for over a year and partial responses. The company plans to expand its ADXS-HOT program with a new study in early prostate cancer. Financially, Advaxis reported cash reserves of $48.1 million, providing a runway into Q3 2023, alongside increased R&D expenses of $4.34 million for the quarter.

Advaxis, Inc. (NASDAQ: ADXS) announced positive updated results from its ongoing Phase 1/2 study of ADXS-503 in combination with KEYTRUDA^®. The study revealed a disease control rate of 44% in patients with non-small-cell lung cancer (NSCLC) who progressed on pembrolizumab. Notably, durable clinical benefits were observed, with some patients maintaining stable disease beyond one year. The combination therapy exhibited a favorable safety profile. The company aims to expand its clinical research, including a Phase 1 study for ADXS-504 targeting early prostate cancer.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company, has announced it will present data from Part B of its Phase 1 study on ADXS-503, in combination with pembrolizumab, at the ASCO Annual Meeting on June 4-8, 2021. The presentation will focus on an off-the-shelf multi-neoantigen vector designed for patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on pembrolizumab. The session is scheduled for June 4, 2021, at 9:00 AM (EDT), with abstract number 2616.

Advaxis, Inc. (NASDAQ: ADXS) announced a major milestone in its partnership with OS Therapies for the ADXS-HER2 program aimed at treating osteosarcoma. The recent financing by OS Therapies triggered a milestone payment to Advaxis, enhancing its financial resources as it advances its ADXS-HOT neoantigen program. Advaxis aims to further develop ADXS-503 and ADXS-504, with ongoing clinical studies showing promise. The press release highlights the potential of these therapies, which integrate advanced immunotherapy technology to stimulate anti-tumor immune responses.

Advaxis, Inc. (NASDAQ: ADXS) has received a second milestone payment regarding its licensing agreement for ADXS31-164 (ADXS-HER2) with OS Therapies for treating osteosarcoma. OS Therapies is responsible for a clinical study, having recently secured financing. Advaxis stands to gain additional milestone payments and royalties from future sales. The funding supports Advaxis's ADXS-HOT neoantigen program, with ongoing clinical studies for ADXS-503 in NSCLC and ADXS-504 for prostate cancer expected to enter the clinic shortly.